A5062435112- Cardiac Valve Diseases and Treatments
- Cardiac Structural Anomalies and Repair
- Mechanical Circulatory Support Devices
- Infective Endocarditis Diagnosis and Management
- Transplantation: Methods and Outcomes
- Aortic Disease and Treatment Approaches
- Cardiac pacing and defibrillation studies
- Tissue Engineering and Regenerative Medicine
- Cardiac Arrest and Resuscitation
- Electrospun Nanofibers in Biomedical Applications
- Viral Infections and Immunology Research
- Renal Transplantation Outcomes and Treatments
- Congenital Heart Disease Studies
- Cardiac and Coronary Surgery Techniques
- Cardiovascular Function and Risk Factors
- Cardiac Imaging and Diagnostics
- Aortic aneurysm repair treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Arrhythmias and Treatments
- Organ Transplantation Techniques and Outcomes
- Organ and Tissue Transplantation Research
- Atrial Fibrillation Management and Outcomes
- Cardiac tumors and thrombi
- Coronary Interventions and Diagnostics
- Infectious Aortic and Vascular Conditions
University of Padua
2016-2025
Consorzio per la Ricerca Sanitaria
2019-2024
Mylan (South Africa)
2023
Azienda Ospedaliera di Padova
1987-2023
Centro Cardiologico Monzino
2023
University Hospital of Zurich
2023
University of Zurich
2023
Imperial College Healthcare NHS Trust
2023
Hammersmith Hospital
2023
San Diego Cardiac Center
2008-2022
Transapical off-pump NeoChord repair is a novel minimally invasive surgical procedure to treat degenerative mitral valve regurgitation. The aim was evaluate 1-year clinical results of the in consecutive cohort patients.Between February 2013 and July 2016, 213 patients were enrolled Independent International Registry. All presented severe regurgitation due flail/prolapse 1 or both leaflets, they all completed postoperative echocardiographic assessment up year. We identified primary end point...
Abstract Background Glutaraldehyde fixation does not guarantee complete tissue biocompatibility in current clinical bioprosthetic heart valves ( BHV s). Particularly, circulating anti‐α G al human antibodies increase significantly from just 10 days after a implantation. The inactivation of such epitope should be mandatory to meet the requirements for perspectively safe application; nevertheless, its quantitative assessment commercially available s has never been carried out. Methods In this...
Early data on the Edwards SAPIEN 3 valve (S3-THV) have shown low rates of paravalvular leaks and vascular complications but relatively high 30-day permanent pacemaker implantation (PPMI) rates. No direct comparisons clinical outcomes including PPMI are available for S3-THV XT (XT-THV). We aimed to compare in patients treated with two prostheses assess interplay among type, depth rate.Two hundred nine by TAVI were considered. The was associated higher compared XT-THV, both overall subgroups...
Bioprosthetic heart valves (BHVs) are commonly used to replace severely diseased but their susceptibility structural valve degeneration (SVD) limits use in young patients. We hypothesized that antibodies against immunogenic glycans present on BHVs, particularly the xenoantigens galactose-α1,3-galactose (αGal) and N-glycolylneuraminic acid (Neu5Gc), could mediate deterioration through calcification. established a large longitudinal prospective international cohort of patients (n = 1668, 34 ±...
Bladder cancer (BC) is among the most common malignancies in world and a relevant cause of mortality. BC one frequent causes for bladder removal through radical cystectomy, gold-standard treatment localized muscle-invasive some cases high-risk, non-muscle-invasive cancer. In order to restore urinary functionality, an autologous intestinal segment has be used create diversion. However, several complications are associated with bowel-tract removal, affecting patients’ quality life. The present...
We assessed the safety and effectiveness of a selective percutaneous revascularization strategy before TAVI in single-center prospective registry.Management Coronary Artery Disease (CAD) Transcatheter Aortic Valve Implantation (TAVI) is not yet established.Percutaneous Intervention (PCI) was scheduled proximal-to-mid coronary segment lesions on major branches. performed by trans-femoral, trans-subclavian or trans-apical approach, using either self-expandable III generation CoreValve...
Pharmacokinetic modeling supports trough monitoring of everolimus, but prospective data comparing this approach versus mycophenolate mofetil (MMF) in de novo cardiac transplant recipients are currently unavailable.In a 12-month multicenter open-label study, patients received everolimus (trough level 3-8 ng/mL) with reduced cyclosporine A (CsA) or MMF (3 g/day) standard CsA, both corticosteroids+/-induction therapy.In total, 176 were randomized (everolimus 92, 84). Mean creatinine clearance...
Mechanical circulatory support devices have been increasingly used for long-term support. We reviewed outcomes in all patients supported with a SynCardia total artificial heart (TAH) more than 1 year to assess its safety As of December 2011, 47 who received the TAH from 10 centers worldwide were included this retrospective study. Clinical data collected on survival, infections, thromboembolic and hemorrhagic events, device failures, antithrombotic therapy. The mean age was 50 ± 1.57 years,...